Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2006-04-25
2006-04-25
Falk, Anne-Marie (Department: 1632)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C424S093100, C424S093200, C424S093600, C435S320100, C514S04400A
Reexamination Certificate
active
07033834
ABSTRACT:
A method for producing viral gene delivery vehicles which can be transferred to pre-selected cell types by using targeting conjugates. The gene delivery vehicles comprise: 1) the gene of interest; and 2) a viral capsid or envelope carrying a member of a specific binding pair, the counterpart of which is not directly associated with the surface of the target cell. These vehicles can be rendered unable to bind to their natural cell receptor. The targeting conjugates include the counterpart member of the specific binding pair, linked to a targeting moiety which is a cell-type specific ligand (or fragments thereof). The number of the specific binding pair present on the viral vehicles can be, for example, an immunoglobulin binding moiety (e.g., capable of binding to a Fc fragment, protein A, protein G, FcR or an anti-Ig antibody), or biotin, avidin or streptavidin. The virus' outer membrane or capsid may contain a substance which mediates entrance of the gene delivery vehicle into the target cell. Due to the specificity of the ligand, the binding pair's high affinity, and the gene delivery vehicle's inability to be targeted when used alone, the universality of the method for gene delivery, together with its high cell type selectively can be achieved by using various targeting conjugates.
REFERENCES:
patent: 5559099 (1996-09-01), Wickham et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6040174 (2000-03-01), Imler et al.
patent: 0496074 (1992-07-01), None
patent: 2649119 (1991-01-01), None
patent: WO/9222332 (1992-12-01), None
patent: WO/9309221 (1993-05-01), None
patent: WO/9412626 (1994-06-01), None
patent: WO/9416734 (1994-08-01), None
patent: WO/9526412 (1995-10-01), None
patent: WO/9700326 (1997-01-01), None
Boado, R.J. (1995)Adv. Drug Deliv, Rev.,15:73-107.
Curiel et al. (1994)Virology,198:577-585.
Etienne-Julian et al. (1992)J. Gen Virol.,(1992) 73: 3251-3255.
Friedmann, T. “Overcoming the obstacles to gene therapy.”Sci. Am.Jun. 1997 pp. 96-101.
Marin et al. (1994)Gene Therapy,1(2):s15.
Nilson et al. (1994)Gene Therapy,1(2):s17.
Orkin, et al. “Report and recommendations of the panel to assess the NIH investment in research on gene therapy.” Dec. 1995.
Roux et al. (1989)Proc. Natl. Acad. Sci.,86:9079-9083.
Russell et al. (1993)Nucleic Acids Research,21(5):1081-1085.
Truong et al. (1993)Proc. Intern. Symp. Control, Release Bioact. Mater.,20: 474-475.
Verma et al. Gene therapy—promises, problems and prospects. (Sep. 1997)Nature389:239-242.
Zatloukal et al., (1993)J. Cell Biochem.,17(d):129.
Valerio Domenico
Van Beusechem Victor Willem
Crucell Holland B.V.
Falk Anne-Marie
TraskBritt
LandOfFree
Methods and means for targeted gene delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and means for targeted gene delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and means for targeted gene delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528111